Controlled cross-over study in normal subjects of naloxone-preceding-lactate infusions; respiratory and subjective responses: relationship to endogenous opioid system, suffocation false alarm theory and childhood parental loss.
BACKGROUND
The expanded suffocation false alarm theory (SFA) hypothesizes that dysfunction in endogenous opioidergic regulation increases sensitivity to CO2, separation distress and panic attacks. In panic disorder (PD) patients, both spontaneous clinical panics and lactate-induced panics markedly increase tidal volume (TV), whereas normals have a lesser effect, possibly due to their intact endogenous opioid system. We hypothesized that impairing the opioidergic system by naloxone could make normal controls parallel PD patients' response when lactate challenged. Whether actual separations and losses during childhood (childhood parental loss, CPL) affected naloxone-induced respiratory contrasts was explored. Subjective panic-like symptoms were analyzed although pilot work indicated that the subjective aspect of anxious panic was not well modeled by this specific protocol.


METHODS
Randomized cross-over sequences of intravenous naloxone (2 mg/kg) followed by lactate (10 mg/kg), or saline followed by lactate, were given to 25 volunteers. Respiratory physiology was objectively recorded by the LifeShirt. Subjective symptomatology was also recorded.


RESULTS
Impairment of the endogenous opioid system by naloxone accentuates TV and symptomatic response to lactate. This interaction is substantially lessened by CPL.


CONCLUSIONS
Opioidergic dysregulation may underlie respiratory pathophysiology and suffocation sensitivity in PD. Comparing specific anti-panic medications with ineffective anti-panic agents (e.g. propranolol) can test the specificity of the naloxone+lactate model. A screen for putative anti-panic agents and a new pharmacotherapeutic approach are suggested. Heuristically, the experimental unveiling of the endogenous opioid system impairing effects of CPL and separation in normal adults opens a new experimental, investigatory area.
Preter
M
M
Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, NY, USA. mpreter@gmail.com
Lee
S H
SH
Petkova
E
E
Vannucci
M
M
Kim
S
S
Klein
D F
DF
D000293:Adolescent; D000328:Adult; D001010:Anxiety, Separation / Q000378:metabolism*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D019344:Lactic Acid; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology; D018847:Opioid Peptides / Q000187:drug effects / Q000378:metabolism*; D016584:Panic Disorder / Q000378:metabolism*; D012143:Respiratory Physiological Phenomena / Q000187:drug effects
D018847:Opioid Peptides; D019344:Lactic Acid; D009270:Naloxone
BMJ. 2001 May 12;322(7295):1145
11348907
J Pharmacol Exp Ther. 1999 May;289(2):840-6
10215661
Am J Prev Med. 2009 Nov;37(5):389-96
19840693
Behav Res Ther. 1990;28(6):469-79
2076084
Stud Health Technol Inform. 2004;108:133-41
15718639
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2041-6
11172072
Eur Arch Psychiatry Clin Neurosci. 2003 Dec;253(6):313-20
14714121
Brain Res. 1988 Feb 9;440(2):285-92
3359215
Cephalalgia. 2004 Jan;24(1):54-9
14687014
Arch Gen Psychiatry. 1985 Jul;42(7):709-19
4015313
Psychopharmacologia. 1964 Jun 8;5:397-408
14194683
Arch Gen Psychiatry. 1984 Aug;41(8):764-70
6742978
Arch Gen Psychiatry. 1992 Feb;49(2):109-16
1550463
J Physiol. 1995 Oct 1;488 ( Pt 1):77-84
8568667
Biol Psychiatry. 1982 Nov;17(11):1243-76
6295518
Handb Exp Pharmacol. 2005;(169):449-68
16594268
Arch Gen Psychiatry. 1993 Apr;50(4):280-5
8466389
Prim Care Companion J Clin Psychiatry. 2008;10(5):376-83
19158976
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):265-72
16309810
Arch Gen Psychiatry. 1993 Apr;50(4):306-17
8466392
J Clin Psychiatry. 2006 Aug;67(8):1179-86
16965194
Med Sci Sports Exerc. 1982;14(5):377-81
7154893
Am J Public Health. 2009 Nov;99(11):2049-54
19762669
Biometrics. 2008 Sep;64(3):931-939
18177460
Science. 2003 Oct 10;302(5643):237-9
14551424
Am J Psychiatry. 1984 Aug;141(8):995-7
6087689
Arch Gen Psychiatry. 1992 Aug;49(8):624-9
1637252
Arch Gen Psychiatry. 2009 Jan;66(1):64-71
19124689
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2035-40
11172071
Anxiety. 1996;2(6):296-302
9160637
Pain. 2009 May;143(1-2):92-6
19304391
Clin J Pain. 2005 Nov-Dec;21(6):478-83
16215332
Psychopathology. 1984;17 Suppl 1:56-65
6369368
Am J Psychiatry. 1993 Aug;150(8):1149-57
8392296
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2029-34
11172070
Compr Psychiatry. 2002 Jul-Aug;43(4):269-78
12107864
J Appl Physiol (1985). 1985 May;58(5):1415-20
3158633
Am J Psychiatry. 1997 Nov;154(11):1557-65
9356564
Mol Psychiatry. 1999 Mar;4(2):163-72
10208448
Psychiatry Res. 2007 Jan 15;149(1-3):309-14
17156855
Neuropsychopharmacology. 2002 Jul;27(1):85-91
12062909
JAMA. 2009 Jun 3;301(21):2252-9
19491187
J Neurophysiol. 2002 Sep;88(3):1500-11
12205170
J Clin Psychiatry. 1986 Oct;47 Suppl:21-30
3531189
Am J Psychiatry. 1994 Jun;151(6):927-9
8185008
Psychiatry Res. 1987 Feb;20(2):97-105
3575564
Am J Psychiatry. 1984 Jul;141(7):857-61
6428243
J Addict Dis. 2006;25(1):23-31
16597570
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):603-12
17765379